Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

Teva's second phase III study of SD-809 in TD shows statistically significant results A phase III clinical trial, AIM-TD, evaluating Teva Pharmaceutical Industries' SD-809 (deutetrabenazine) to treat tardive dyskinesia (TD) demonstrated a statistically valid treatment benefit. Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Intra-Cellular Therapies’ schizophrenia drug fails in phase 3 trial
By PBR Staff Writer
Intra-Cellular Therapies’ experimental schizophrenia drug, ITI-007, has failed a Phase 3 trial.
Contract Research & Services > Clinical Trials > News
Novartis and Amgen’s erenumab succeeds in phase 3 study in migraine prevention
By PBR Staff Writer
A phase 3 clinical trial evaluating erenumab (AMG 334) in episodic migraine prevention has met its primary endpoint, demonstrating a statistically significant reduction in monthly migraine days versus placebo.
Contract Research & Services > Clinical Trials > News

Contract Research

Oncodesign to buy GSK's French research center
Oncodesign has agreed to acquire the François Hyafil Research Centre located in Villebon-sur-Yvette (Essonne) from GSK, part of the Paris Saclay innovation cluster, including transfer of the team of highly qualified drug discovery staff located at the site (anticipated to be 57 employees).
Contract Research & Services > Contract Research > News
Bristol-Myers to test Opdivo with Nektar Therapeutics drug in five tumor types
By PBR Staff Writer
Bristol-Myers Squibb (BMS) is evaluating the use of its cancer immunotherapy, Opdivo, in combination with an experimental drug from Nektar Therapeutics to treat several cancers.
Contract Research & Services > Contract Research > News

Contract Services

ProNAi secures global rights to Chk1 inhibitor cancer drug candidate CCT245737
Sareum's co-investment partner, the CRT Pioneer Fund, has licensed exclusive and worldwide rights for the Chk1 inhibitor cancer drug candidate CCT245737 (to be renamed PNT737) to ProNAi Therapeutics.
Contract Research & Services > Contract Services > News
BioLineRx in-licenses novel treatment for liver failure conditions
BioLineRx has signed an exclusive, worldwide agreement with BGN Technologies, the Technology Transfer Company of Ben-Gurion University, and Hadasit, the Technology Transfer Company of Hadassah Medical Organization, for the in-licensing of a novel treatment for various liver failure conditions such as end-stage liver disease (ESLD) and for conditions potentially leading to liver failure such as non-alcoholic steatohepatitis (NASH).
Contract Research & Services > Contract Services > News